Add BrightSurf on Google Email

Metabolic response behind reduced cancer cell growth

A study published in Cell Death & Disease found that inhibiting the EZH2 protein can reduce cancer cell growth in multiple myeloma. The researchers discovered that certain metabolic pathways are altered in cells sensitive to EZH2 inhibition, providing potential markers for treatment response.

SourceUppsala University·JournalCell Death and Disease·DateFeb 12, 2021

Senolysis by glutaminolysis inhibition ameliorates various age-associated disorders

A collaborative research group identified an inhibitor of the glutamate metabolic enzyme GLS1 that selectively eliminates senescent cells in vivo. Administration of GLS1 inhibitors to aged mice removed senescent cells from various organs, ameliorating tissue dysfunction and age-related diseases such as obese diabetes and arteriosclerosis.

Patient-reported outcomes from the randomized phase III CROWN study of first-line Lorlatinib versus in ALK+ NSCLC

The phase III CROWN study showed that lorlatinib significantly improved progression-free survival compared to crizotinib in patients with previously untreated advanced ALK-positive NSCLC. Patient-reported outcomes also indicated comparable time to treatment deterioration for lung cancer symptoms between the two treatments.

Acta Pharmaceutica Sinica Bvolume 10, issue 12 publishes

This issue of APSB features studies on the anticancer effects of berberine, baicalein's potent antivirus ability against HSV-1, and a new class of PDE10A inhibitors for treating PAH. Additionally, several articles explore innovative drug delivery systems and novel targets for cancer therapy.

SourceCompuscript Ltd·JournalActa Pharmaceutica Sinica B·DateJan 11, 2021

Uncovering basic mechanisms of intestinal stem cell self-renewal and differentiation

Researchers improved understanding of intestinal stem cells' renewal and differentiation into specialized cell types. They identified a specific Wnt/planar cell polarity pathway regulating intestinal stem cell self-renewal and lineage decisions, crucial for treating diseases like diabetes and colorectal cancer.

Cells resistant to treatment already present before diagnosis of adult leukaemia

Researchers discovered that cancer cells resistant to adult leukemia treatment are already present in tumors before diagnosis, according to a new study published by IRB Barcelona. The study analyzed genome sequencing data from 19 adult patients and found that these resistant cells were undetectable at the time of diagnosis.

Moffitt program bringing patients, scientists together infuses new meaning into research

The Patient Researcher Forum allows patients and researchers to learn from each other, fostering interdisciplinary collaboration. The program has a positive impact on perspectives of both parties, with patients gaining insight into the importance of cancer research and researchers becoming more patient-centered in their work.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalTranslational Research·DateDec 14, 2020

Study shows that active surveillance holds promise as a treatment option for low-risk thyroid cancer

A study by researchers at Dartmouth's Geisel School of Medicine found that active surveillance can be successfully implemented in patients with low-risk thyroid cancer. The study shows that 91% of patients adhered to the prescribed ultrasonography schedule and retention rates were high, with only 4.5% choosing surgery after two years.

Racial/ethnic minorities comprise small portion of patients referred with AL amyloidosis

A recent study found that racial/ethnic minorities comprise only a small percentage of patients with AL amyloidosis, despite being theoretically at higher risk. Younger age and more severe illness were observed among minority patients, who were also less likely to undergo aggressive treatment with stem cell transplantation.

SourceBoston University School of Medicine·JournalBlood Cancer Journal·DateNov 10, 2020